"The Report Denosumab
(Prolia) (Rheumatoid Arthritis) - Forecast and Market Analysis to
2023 provides information on pricing, market analysis, shares,
forecast, and company profiles for key industry participants. -
MarketResearchReports.biz"
Description
Denosumab (Prolia) (Rheumatoid
Arthritis) - Forecast and Market Analysis to 2023
Summary
Rheumatoid arthritis (RA) is a
chronic autoimmune disease which causes inflammation and deformity of
the joints . It affects over seven million individuals in the 10MM
covered in this report (US, France, Germany, Italy, Spain, UK, Japan,
Australia, China, and India) and the prevalence is expected to grow
to just over 8.5 million individuals by 2023. The anti-TNFs have been
effective in treating the signs and symptoms of RA and inhibiting
progression to erosive bone disease. However, the landscape is
quickly changing with the introduction of biosimilars, novel
biologics, and a class of oral therapies known as JAK inhibitors, all
of which will change the market dynamics between 2013 and 2023. With
the anti-TNFs as extremely effective therapies for RA, the market is
extremely competitive for new entrants and will undergo further
pressure as biosimilars are approved and launch.
Denosumab is a fully-human,
immunoglobulin G1 (IgG2) mAb against RANKL that is in Phase III of
development for RA patients with active, erosive bone disease. The
Phase III clinical program is currently supported by Daiichi Sankyo
for use in the Japanese population. Denosumab was once under
investigation for RA by Amgen, which owns the rights to the molecule
in the US and 5EU. However, a Phase II trial was completed in 2007,
with no further development, and Amgen does not list denosumab for RA
in its March 2014 pipeline on the companys webpage.
View Full Report at
http://www.marketresearchreports.biz/analysis/247173
Scope
- Overview of Rheumatoid
Arthritis, including epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an overview on the
competitive landscape.
- Detailed information on
Denosumab including product description, safety and efficacy profiles
as well as a SWOT analysis.
- Sales forecast for Denosumab
for the top country from 2013 to 2023.
- Sales information covered
for Japan.
Reasons
to buy
- Understand and capitalize by
identifying products that are most likely to ensure a robust return.
- Stay ahead of the
competition by understanding the changing competitive landscape for
Rheumatoid Arthritis.
- Effectively plan your M&A
and partnership strategies by identifying drugs with the most
promising sales potential.
- Make more informed business
decisions from insightful and in-depth analysis of Denosumab
performance.
- Obtain sales forecast for
Denosumab from 2013-2023 in top country (Japan).
Download
Detail Report With Complete TOC at
Table
of Content
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 13
3 Disease Overview 14
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 14
3.2 Symptoms 18
3.3 Prognosis 19
3.4 Quality of Life 19
4 Disease Management 20
4.1 Diagnosis and Treatment Overview 20
4.1.1 Diagnosis 20
4.1.2 Treatment Guidelines 22
4.1.3 Leading Prescribed Drugs for the Treatment of RA 32
4.1.4 Clinical Practice 34
5 Competitive Assessment 39
5.1 Overview 39
6 Unmet Need and Opportunity 41
6.1 Overview 41
6.2 Development of Cost-Effective Therapies 42
6.2.1 Unmet Need 42
6.2.2 Gap Analysis 43
6.2.3 Opportunity 43
6.3 Biomarkers to Predict Responsiveness to Therapy 44
6.3.1 Unmet Need 44
6.3.2 Gap Analysis 46
6.3.3 Opportunity 46
7 Pipeline Assessment 53
7.1 Overview 53
Browse
Latest News at http://www.marketresearchreports.biz/articles
About
Us
MarketResearchReports.biz is
the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Browse
Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz
Contact
Us
Office:
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA: Canada Toll Free:
866-997-4948
No comments:
Post a Comment